undamentalytics Newsletter

Miller Richard A Md: insider trades

Chief executive at Corvus Pharmaceuticals, Inc. 22 open-market purchases and no sales not made under a pre-set plan, reported from May 16, 2016 to May 20, 2026.

Would copying Miller Richard A Md’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 5 purchases have 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on May 17, 2016 into $3,040 by November 2, 2026, −10.8% a year. The copy held shares only 38% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $19,569, +6.6% a year (the S&P 500 held throughout made $43,687, +15.2% a year). Beta against the index was 0.20. Twelve months after each report, the average purchase was −37.1% against the S&P 500 (median −50.4%), and 20% beat it. Measured from the trade date, the insider’s own timing, the average was −29.7%.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$20.0k$40.0k 201620182020202220242026 $43.7k$19.6k$3.0k
Copying Miller Richard A MdS&P 500, same days investedS&P 500, held throughout $10,000 copying Miller Richard A Md’s open-market purchases from May 17, 2016, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
−10.8%
S&P 500, same days invested
+6.6% (held throughout +15.2%)
Time in shares
38%
Sharpe ratio (S&P 500)
−0.09 (0.75)
Biggest drop (S&P 500)
−88% (−34%)
Market sensitivity (beta)
0.20
Purchases copied
6

Trade by trade

Miller Richard A Md: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 6 +5.2% +12.1% 67% 4 1.44 0.25 No reliable evidence
Purchases, 6 months after the report 5 −4.9% −5.8% 40% 3 — — Not enough years
Purchases, 12 months after the report 5 −37.1% −50.4% 20% 3 — — Not enough years
Purchases, 12 months after the trade 5 −29.7% −43.2% 20% 3 — — Not enough years
Sales, 3 months after the report 0 — — — — — — Not enough years
Sales, 12 months after the report 0 — — — — — — Not enough years
Sales, 12 months after the trade 0 — — — — — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Corvus Pharmaceuticals, Inc. CRVS President and CEO220May 16, 2016May 20, 2026

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
May 20, 2026May 18, 2026 CRVS Purchase $83,453 +7.2%not yetnot yet
May 7, 2024May 6, 2024 CRVS Purchase $999,307 not yetnot yetnot yet
December 15, 2022December 13, 2022 CRVS Purchase $44,800 not yetnot yetnot yet
September 28, 2022September 28, 2022 CRVS Purchase $19,000 not yetnot yetnot yet
September 20, 2022September 20, 2022 CRVS Purchase $16,277 not yetnot yetnot yet
June 28, 2022June 24, 2022 CRVS Purchase $10,150 not yetnot yetnot yet
April 1, 2022March 31, 2022 CRVS Purchase $24,600 not yetnot yetnot yet
March 17, 2022March 15, 2022 CRVS Purchase $44,700 not yetnot yetnot yet
August 23, 2021August 20, 2021 CRVS Purchase $19,300 not yetnot yetnot yet
May 5, 2021May 4, 2021 CRVS Purchase $99,999 not yetnot yetnot yet
February 17, 2021February 17, 2021 CRVS Purchase $350,000 not yetnot yetnot yet
November 14, 2019November 12, 2019 CRVS Purchase $44,997 not yetnot yetnot yet
August 8, 2019August 6, 2019 CRVS Purchase $26,750 not yetnot yetnot yet
June 17, 2019June 13, 2019 CRVS Purchase $40,841 not yetnot yetnot yet
June 11, 2019June 7, 2019 CRVS Purchase $53,064 not yetnot yetnot yet
December 31, 2018December 27, 2018 CRVS Purchase $65,800 not yetnot yetnot yet
December 26, 2018December 20, 2018 CRVS Purchase $43,950 not yetnot yetnot yet
December 10, 2018December 6, 2018 CRVS Purchase $29,950 −32.3%−53.4%−46.6%
March 12, 2018March 12, 2018 CRVS Purchase $850,000 +20.1%−63.9%−59.7%
November 22, 2017November 20, 2017 CRVS Purchase $107,900 −33.0%−50.4%−43.2%
June 13, 2017June 9, 2017 CRVS Purchase $247,040 +52.6%+4.5%+13.6%
May 16, 2016May 12, 2016 CRVS Purchase $302,982 +16.9%−22.1%−12.4%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Miller Richard A Md traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.